CONTEXT: The prognostic value of plasma levels of adiponectin, an adipocytokine with antiatherogenic, antiinflammatory, and insulin-sensitizing effects, is contentious. OBJECTIVE: The objective of the study was to investigate whether plasma adiponectin levels predict cardiovascular (CV) events and mortality in high-risk coronary artery disease (CAD) patients. DESIGN, SETTING, PARTICIPANTS, AND MAIN OUTCOME MEASURE: We measured plasma adiponectin and examined its impact on the incidence of CV deaths and events at follow-up in the context of all potentially relevant background covariates in 712 high-risk patients of the Genetic and ENvironmental factors in Coronary Atherosclerosis study who underwent coronary angiography for suspected CAD. Based on the population plasma adiponectin median (6.38 microg/ml, interquartile range 4.2-10.2), we split the patients in a high- and a low-plasma adiponectin subgroup. After a median follow-up of 3.8 years (interquartile range 3.3-4.3 yr), outcome data were obtained in 100% of the patients and 45 CV deaths (6.4%) were recorded. Kaplan-Meier analysis unexpectedly showed a higher CV death rate in high-plasma adiponectin than low-plasma adiponectin patients. By contrast, multivariate Cox regression analysis, in which potential confounders, including ongoing medical treatment, were considered, showed no impact of plasma adiponectin on CV death. Similar negative results were obtained using the propensity score that considered all relevant covariables and medical treatment rate, which differed between the high- and low-plasma adiponectin group. CONCLUSIONS: In high-risk CAD patients, plasma adiponectin above the median (6.38 microg/ml) implies a paradoxical higher risk of CV death. However, when relevant covariates that differ between high- and low-plasma adiponectin groups are considered, this association wanes, indicating that the clustering of plasma adiponectin with other covariates can abolish its impact on CV prognosis.
CONTEXT: The prognostic value of plasma levels of adiponectin, an adipocytokine with antiatherogenic, antiinflammatory, and insulin-sensitizing effects, is contentious. OBJECTIVE: The objective of the study was to investigate whether plasma adiponectin levels predict cardiovascular (CV) events and mortality in high-risk coronary artery disease (CAD) patients. DESIGN, SETTING, PARTICIPANTS, AND MAIN OUTCOME MEASURE: We measured plasma adiponectin and examined its impact on the incidence of CV deaths and events at follow-up in the context of all potentially relevant background covariates in 712 high-risk patients of the Genetic and ENvironmental factors in Coronary Atherosclerosis study who underwent coronary angiography for suspected CAD. Based on the population plasma adiponectin median (6.38 microg/ml, interquartile range 4.2-10.2), we split the patients in a high- and a low-plasma adiponectin subgroup. After a median follow-up of 3.8 years (interquartile range 3.3-4.3 yr), outcome data were obtained in 100% of the patients and 45 CV deaths (6.4%) were recorded. Kaplan-Meier analysis unexpectedly showed a higher CV death rate in high-plasma adiponectin than low-plasma adiponectinpatients. By contrast, multivariate Cox regression analysis, in which potential confounders, including ongoing medical treatment, were considered, showed no impact of plasma adiponectin on CV death. Similar negative results were obtained using the propensity score that considered all relevant covariables and medical treatment rate, which differed between the high- and low-plasma adiponectin group. CONCLUSIONS: In high-risk CAD patients, plasma adiponectin above the median (6.38 microg/ml) implies a paradoxical higher risk of CV death. However, when relevant covariates that differ between high- and low-plasma adiponectin groups are considered, this association wanes, indicating that the clustering of plasma adiponectin with other covariates can abolish its impact on CV prognosis.
Authors: Linda Broer; Julia Raschenberger; Joris Deelen; Massimo Mangino; Veryan Codd; Kirsi H Pietiläinen; Eva Albrecht; Najaf Amin; Marian Beekman; Anton J M de Craen; Christian Gieger; Margot Haun; Peter Henneman; Christian Herder; Iiris Hovatta; Annika Laser; Lyudmyla Kedenko; Wolfgang Koenig; Barbara Kollerits; Eeva Moilanen; Ben A Oostra; Bernhard Paulweber; Lydia Quaye; Aila Rissanen; Michael Roden; Ida Surakka; Ana M Valdes; Katriina Vuolteenaho; Barbara Thorand; Ko Willems van Dijk; Jaakko Kaprio; Tim D Spector; P Eline Slagboom; Nilesh J Samani; Florian Kronenberg; Cornelia M van Duijn; Karl-Heinz Ladwig Journal: Eur J Epidemiol Date: 2014-07-27 Impact factor: 8.082
Authors: Alexis L Beatty; Mary H Zhang; Ivy A Ku; Beeya Na; Nelson B Schiller; Mary A Whooley Journal: Atherosclerosis Date: 2011-12-07 Impact factor: 5.162
Authors: Jessica R Singer; Walter Palmas; Jeanne Teresi; Ruth Weinstock; Steven Shea; José A Luchsinger Journal: Diabetes Care Date: 2012-07-06 Impact factor: 19.112
Authors: Martin M Mikkelsen; Troels K Hansen; Jakob Gjedsted; Niels H Andersen; Thomas D Christensen; Vibeke E Hjortdal; Søren P Johnsen Journal: J Cardiothorac Surg Date: 2010-12-14 Impact factor: 1.637
Authors: Maximilian von Eynatten; Dan Liu; Cornelia Hock; Dimitrios Oikonomou; Marcus Baumann; Bruno Allolio; Grigorios Korosoglou; Michael Morcos; Valentina Campean; Kerstin Amann; Jens Lutz; Uwe Heemann; Peter P Nawroth; Angelika Bierhaus; Per M Humpert Journal: Diabetes Date: 2009-06-09 Impact factor: 9.461